Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Spergel

Showing results (511-520 of 590) with videos related to

Pageof 59
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|May 20, 2024
Nonepithelial Gene Expression Correlates With Symptom Severity in Adults With Eosinophilic EsophagitisSeung Kim, Netali Ben-Baruch Morgenstern, Kasumi Osonoi, et al.
The Journal of Allergy and Clinical Immunology|July 26, 2024
Long-term durability between parent and child patient-reported outcomes in eosinophilic esophagitisLisa J Martin, Xue Zhang, Mirna Chehade, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 26, 2023
Esophageal Epithelium and Lamina Propria Are Unevenly Involved in Eosinophilic EsophagitisGirish Hiremath, Lili Sun, Margaret H Collins, et al.
Gastro Hep Advances|December 16, 2025
Patient-Reported Outcome Scores Are Comparable in Multiregional Versus Uniregional Eosinophilic EsophagitisMargaret H Collins, Zhaoxing Pan, Guang-Yu Yang, et al.
Journal of Medicinal Chemistry|August 20, 2004
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activityPing Chen, Arthur M Doweyko, Derek Norris, et al.
The Journal of Allergy and Clinical Immunology|August 28, 2020
Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi studyTimothy E Dribin, Hugh A Sampson, Carlos A Camargo, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid ArthritisSteven H Spergel, Michael E Mertzman, James Kempson, et al.
Journal of Medicinal Chemistry|July 18, 2019
Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)Ryan Moslin, Yanlei Zhang, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|May 10, 1996
Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicityP Chen, P T Cheng, M Alam, et al.
Translational Science of Rare Diseases|January 16, 2018
Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)Katherine Cheng, Sandeep K Gupta, Susanna Kantor, et al.
Pageof 59

Showing results (511-520 of 590) with videos related to

Sort By:
Pageof 59
The Journal of Allergy and Clinical Immunology. in Practice|May 20, 2024
Nonepithelial Gene Expression Correlates With Symptom Severity in Adults With Eosinophilic EsophagitisSeung Kim, Netali Ben-Baruch Morgenstern, Kasumi Osonoi, et al.
The Journal of Allergy and Clinical Immunology|July 26, 2024
Long-term durability between parent and child patient-reported outcomes in eosinophilic esophagitisLisa J Martin, Xue Zhang, Mirna Chehade, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 26, 2023
Esophageal Epithelium and Lamina Propria Are Unevenly Involved in Eosinophilic EsophagitisGirish Hiremath, Lili Sun, Margaret H Collins, et al.
Gastro Hep Advances|December 16, 2025
Patient-Reported Outcome Scores Are Comparable in Multiregional Versus Uniregional Eosinophilic EsophagitisMargaret H Collins, Zhaoxing Pan, Guang-Yu Yang, et al.
Journal of Medicinal Chemistry|August 20, 2004
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activityPing Chen, Arthur M Doweyko, Derek Norris, et al.
The Journal of Allergy and Clinical Immunology|August 28, 2020
Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi studyTimothy E Dribin, Hugh A Sampson, Carlos A Camargo, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid ArthritisSteven H Spergel, Michael E Mertzman, James Kempson, et al.
Journal of Medicinal Chemistry|July 18, 2019
Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)Ryan Moslin, Yanlei Zhang, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|May 10, 1996
Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicityP Chen, P T Cheng, M Alam, et al.
Translational Science of Rare Diseases|January 16, 2018
Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)Katherine Cheng, Sandeep K Gupta, Susanna Kantor, et al.
Pageof 59